Literature DB >> 10471088

Neuroprotective effects of early vs. late administration of dantrolene in experimental status epilepticus.

M Niebauer1, M Gruenthal.   

Abstract

We examined the effects of dantrolene, an inhibitor of intracellular calcium release, on hippocampal neuronal damage associated with 140 min of limbic status epilepticus in the rat. Dantrolene (10 mg/kg i.p.) was administered after either 30 min or 140 min of status epilepticus. Early administration was associated with a significant reduction in the amount of neuronal injury in all hippocampal subregions, while late administration was associated with less neuronal injury in area CA3 only. These findings suggest that a substantial portion of seizure-induced hippocampal injury is associated with release of calcium from intracellular stores, and that early administration of dantrolene may be a useful adjunct to anticonvulsant treatment of status epilepticus.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10471088     DOI: 10.1016/s0028-3908(99)00059-3

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  12 in total

1.  Localization and phenotype-specific expression of ryanodine calcium release channels in C57BL6 and DBA/2J mouse strains.

Authors:  Wei Huang; Wei Xing; Daniel A Ryskamp; Claudio Punzo; David Križaj
Journal:  Exp Eye Res       Date:  2011-09-14       Impact factor: 3.467

2.  Hypothermia reduces calcium entry via the N-methyl-D-aspartate and ryanodine receptors in cultured hippocampal neurons.

Authors:  Kristin F Phillips; Laxmikant S Deshpande; Robert J DeLorenzo
Journal:  Eur J Pharmacol       Date:  2012-10-17       Impact factor: 4.432

3.  Dantrolene inhibits the calcium plateau and prevents the development of spontaneous recurrent epileptiform discharges following in vitro status epilepticus.

Authors:  Nisha Nagarkatti; Laxmikant S Deshpande; Dawn S Carter; Robert J DeLorenzo
Journal:  Eur J Neurosci       Date:  2010-06-28       Impact factor: 3.386

4.  Long-term dantrolene treatment reduced intraneuronal amyloid in aged Alzheimer triple transgenic mice.

Authors:  Zhen Wu; Bin Yang; Chunxia Liu; Ge Liang; Maryellen F Eckenhoff; Weixia Liu; Stephen Pickup; Qingcheng Meng; Yuke Tian; Shitong Li; Huafeng Wei
Journal:  Alzheimer Dis Assoc Disord       Date:  2015 Jul-Sep       Impact factor: 2.703

5.  Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2.

Authors:  Jing Liu; Tie-Shan Tang; Huiping Tu; Omar Nelson; Emily Herndon; Duong P Huynh; Stefan M Pulst; Ilya Bezprozvanny
Journal:  J Neurosci       Date:  2009-07-22       Impact factor: 6.167

6.  Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3.

Authors:  Xi Chen; Tie-Shan Tang; Huiping Tu; Omar Nelson; Mark Pook; Robert Hammer; Nobuyuki Nukina; Ilya Bezprozvanny
Journal:  J Neurosci       Date:  2008-11-26       Impact factor: 6.167

7.  Dynamic regulation of ryanodine receptor type 1 (RyR1) channel activity by Homer 1.

Authors:  Wei Feng; Jiancheng Tu; Pierre Pouliquin; Elaine Cabrales; Xiaohua Shen; Angela Dulhunty; Paul F Worley; Paul D Allen; Isaac N Pessah
Journal:  Cell Calcium       Date:  2007-08-17       Impact factor: 6.817

8.  Pharmacological blockade of the calcium plateau provides neuroprotection following organophosphate paraoxon induced status epilepticus in rats.

Authors:  Laxmikant S Deshpande; Robert E Blair; Beverly A Huang; Kristin F Phillips; Robert J DeLorenzo
Journal:  Neurotoxicol Teratol       Date:  2016-05-17       Impact factor: 3.763

9.  Sustained Hippocampal Synaptic Pathophysiology Following Single and Repeated Closed-Head Concussive Impacts.

Authors:  John McDaid; Clark A Briggs; Nikki M Barrington; Daniel A Peterson; Dorothy A Kozlowski; Grace E Stutzmann
Journal:  Front Cell Neurosci       Date:  2021-03-31       Impact factor: 5.505

Review 10.  Dantrolene: mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit.

Authors:  Susanne Muehlschlegel; John R Sims
Journal:  Neurocrit Care       Date:  2008-08-12       Impact factor: 3.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.